Skip to main content
PMC home page
Cancer Science logoLink to Cancer Science
. 2005 Aug 19;95(4):283–289. doi: 10.1111/j.1349-7006.2004.tb03204.x

Development of gene therapy to target pancreatic cancer

Teruhiko Yoshida 1,✉, Shumpei Ohnami 2,✉, Kazunori Aoki 3,✉
PMCID: PMC11158832  PMID: 15072584

Abstract

Pancreatic cancer remains one of the most difficult cancers to treat. Its high propensity to infiltrate and metastasize early from a small primary focus necessitates development of a new therapy which can track down the disseminated cancer cells in vivo. Gene therapy may offer new opportunities for a variety of targeting strategies, and we review here some of our work related to the development of targeted gene therapy: 1) Targeting by specific molecular abnormality: Many pancreatic cancer cells show “addiction” to K‐as mutation, while normal cells appear resistant to suppression of K‐ras‐mediated signaling by antisense K‐ras RNA expression adenoviral vector. 2) Targeting by in vivo tumor characteristics: In a peritoneal dissemination model, intraperitoneal lipofection/polyfection can deliver and express transgenes highly preferentially in tumor nodules. 3) Targeting by vector: An efficient protocol for construction of an adenovirus expression vector library has been developed, which will enable a direct functional selection of fiber knob‐modified targeting vector species for given cells. 4) Targeting by tumor immunity: Several cytokines not only induce direct cytotoxicity, but are also expected to activate specific immunity to achieve targeted suppression of cancer cells in vivo. Unlike parenteral administration of short‐lived recombinant interferon protein, local interferon gene transfer can provide a target tissue‐restricted distribution and sustained expression, which may improve the efficacy/safety balance of cytokine therapy. Cancer gene therapy development is, in general, at the stage of proof of principles and safety. However, it is an art of integrated science. The recent rapid progress of related sciences and technologies will expand the potential and consolidate the clinical reality of gene therapy.

References

  • 1. Cancer Statistics in Japan, FFCR, 2003.
  • 2. Haller DG. Future directions in the treatment of pancreatic cancer. Semin Oncol 2002; 29: 31–9. [DOI] [PubMed] [Google Scholar]
  • 3. Ryan DP, Willett CG. Management of locally advanced adenocarcinoma of the pancreas. Hematol Oncol Clin North Am 2002; 16: 95–103. [DOI] [PubMed] [Google Scholar]
  • 4. Kaufman HL, DiVito J, Horig H. Immunotherapy for pancreatic cancer: current concepts. Hematol Oncol Clin North Am 2002; 16: 159–97. [DOI] [PubMed] [Google Scholar]
  • 5. Ghadirian P, Lynch HT, Krewski D. Epidemiology of pancreatic cancer: an overview. Cancer Detect Prev 2003; 27: 87–93. [DOI] [PubMed] [Google Scholar]
  • 6. Isaksson B, Jonsson F, Pedersen NL, Larsson J, Feychting M, Permert J. Lifestyle factors and pancreatic cancer risk: a cohort study from the Swedish twin registry. Int J Cancer 2002; 98: 480–2. [DOI] [PubMed] [Google Scholar]
  • 7. Michaud DS. The epidemiology of pancreatic, gallbladder, and other biliary tract cancers. Gastrointest Endosc, 2002; 56: S195–200. [DOI] [PubMed] [Google Scholar]
  • 8. Sakorafas GH, Tsiotou AG, Tsiotos GG. Molecular biology of pancreatic cancer; oncogenes, tumor suppressor genes, growth factors, and their receptors from a clinical perspective. Cancer Treat Rev 2000; 26: 29–52. [DOI] [PubMed] [Google Scholar]
  • 9. Motojima K, Urano T, Nagata Y, Shiku H, Tsunoda T, Kanematsu T. Mutations in the Kirsten‐ras oncogene are common but lack correlation with prognosis and tumor stage in human pancreatic carcinoma. Am J Gastroenterol 1991; 86: 1784–8. [PubMed] [Google Scholar]
  • 10. DiGiuseppe JA, Hruban RH, Offerhaus GJ, Clement MJ, van den Berg FM, Cameron JL, van Mansfeld AD. Detection of K‐ras mutations in mucinous pancreatic duct hyperplasia from a patient with a family history of pancreatic carcinoma. Am J Pathol 1994; 144: 889–95. [PMC free article] [PubMed] [Google Scholar]
  • 11. Cerny WL, Mangold KA, Scarpelli DG. K‐ras mutation is an early event in pancreatic duct carcinogenesis in the Syrian golden hamster. Cancer Res 1992; 52: 4507–13. [PubMed] [Google Scholar]
  • 12. Yanagisawa A, Ohtake K, Ohashi K, Hori M, Kitagawa T, Sugano H, Kato Y. Frequent c‐Ki‐ras oncogene activation in mucous cell hyperplasias of pancreas suffering from chronic inflammation. Cancer Res 1993; 53: 953–6. [PubMed] [Google Scholar]
  • 13. Aoki K, Yoshida T, Sugimura T, Terada M. Liposome‐mediated in vivo gene transfer of antisense K‐ras construct inhibits pancreatic tumor dissemination in the murine peritoneal cavity. Cancer Res 1995; 55: 3810–6. [PubMed] [Google Scholar]
  • 14. Aoki K, Yoshida T, Matsumoto N, Ide H, Sugimura T, Terada M. Suppression of Ki‐ras p21 levels leading to growth inhibition of pancreatic cancer cell lines with Ki‐ras mutation but not those without Ki‐ras mutation. Mol Carcinog 1997; 20: 251–5. [PubMed] [Google Scholar]
  • 15. Niwa H, Yamamura K, Miyazaki J. Efficient selection for high‐expression transfectants with a novel eukaryotic vector. Gene 1991; 108: 193–9. [DOI] [PubMed] [Google Scholar]
  • 16. Ohnami S, Aoki K, Suzuki K, Ohnami S, Hatanaka K, Yoshida K, Sasaki H, Yoshida T. Expression profiles of pancreatic cancer cell lines infected with antisense K‐ras expressing adenoviral vector. Biochem Biophys Res Commun 2003; 309: 798–803. [DOI] [PubMed] [Google Scholar]
  • 17. Nakano M, Aoki K, Matsumoto N, Ohnami S, Terada M, Hibi T, Yoshida T. Suppression of colorectal cancer growth using an adenovirus vector expressing an antisense K‐ras RNA. Mol Ther 2001; 3: 491–9. [DOI] [PubMed] [Google Scholar]
  • 18. Weinstein IB. Addiction to oncogenes‐the Achilles heal of cancer. Science 2002; 297: 63–4. [DOI] [PubMed] [Google Scholar]
  • 19. Villalonga P, Lopez‐Alcala C, Bosch M, Chiloeches A, Rocamora N, Gil J, Marai R, Marshall CJ, Bachs O, Agell N. Calmodulin binds to K‐Ras, but not to H‐ or N‐Ras, and modulates its downstream signaling. Mol Cell Biol 2001; 21: 7345–54. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 20. Ohnami S, Matsumoto N, Nakano M, Aoki K, Nagasaki K, Sugimura T, Terada M, Yoshida T. Identification of genes showing differential expression in antisense K‐ras‐transduced pancreatic cancer cells with suppressed tumorgenicity. Cancer Res 1999; 59: 5565–71. [PubMed] [Google Scholar]
  • 21. Behr JP, Demeneix B, Loeffler JP, Perez‐Mutul J. Efficient gene transfer into mammalian primary endocrine cells with lipopolyamine‐coated DNA. Proc Natl Acad Sci USA 1989; 86: 6982–6. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 22. Boussif O, Lezoualc'h F, Zanta MA, Mergny MD, Scherman D, Demeneix B, Behr JP. A versatile vector for gene and oligonucleotide transfer into cells in culture and in vivo: polyethylenimine. Proc Natl Acad Sci USA 1995; 92: 7297–301. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 23. Aoki K, Furuhata S, Hatanaka K, Maeda M, Remy JS, Behr J‐P, Terada M, Yoshida T. Polyethylenimine‐mediated gene transfer into pancreatic cancer dissemination in the murine peritoneal cavity. Gene Ther 2001; 8: 508–14. [DOI] [PubMed] [Google Scholar]
  • 24. Aoki K, Yoshida T, Matsumot N, Ide H, Sugimura T, Terada M. Gene therapy for peritoneal dissemination of pancreatic cancer by liposome‐mediated transfer of herpes simplex virus thymidine kinase gene. Hum Gene Ther 1997; 8: 1105–13. [DOI] [PubMed] [Google Scholar]
  • 25. Krasnykh V, Douglas JT. Targeted adenoviral vectors I: transductional targeting. In: Curiel DT, Douglas JT, editors. Adenoviral vectors for gene therapy. San Diego : Academic Press; 2002. p. 205–45. [Google Scholar]
  • 26. Nicklin SA, White SJ, Watkins SJ, Hawkins RE, Baker AH. Selective targeting of gene transfer to vascular endothelial cells by use of peptides isolated by phage display. Circulation 2000; 102: 231–7. [DOI] [PubMed] [Google Scholar]
  • 27. Belousova N, Krendelchtchikova V, Curiel DT, Krasnykh V. Modulation of adenovirus vector tropism via incorporation of polypeptide ligands into the fiber protein. J Virol 2002; 76: 8621–31. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 28. Hatanaka K, Ohnami S, Miura Y, Yoshida K, Aoyagi K, Sasaki H, Asaka M, Terada M, Yoshida T, Aoki K. A simple and efficient method for constructing an adenoviral cDNA expression library. Mol Ther 2003; 8: 158–66. [DOI] [PubMed] [Google Scholar]
  • 29. Ozaki K, Yoshida T, Ide H, Saito I, Ikeda Y, Sugimura T, Terada M. Use of von Willebrand factor promoter to transducer suicidal gene to human endothelial cells, HuVEC. Hum Gene Ther 1996; 7: 1483–90. [DOI] [PubMed] [Google Scholar]
  • 30. Furuhata S, Ide H, Miura Y, Yoshida T, Aoki K. Development of a prostatespecific promoter for gene therapy against androgen‐independent prostate cancer. Mol Ther 2003; 3: 366–74. [DOI] [PubMed] [Google Scholar]
  • 31. Hogan WJ, Storb R. Therapeutic applications of non‐myeloablative hematopoietic stem cell transplantation in malignant disease. Immunol Res 2003; 28: 1–11. [DOI] [PubMed] [Google Scholar]
  • 32. Chawla‐Sarkar M, Lindner DJ, Liu Y‐F, Williams BR, Sen GC, Silverman RH, Borden EC. Apoptosis and interferons: role of interferon‐stimulated genes as mediators of apoptosis. Apoptosis 2003; 8: 237–49. [DOI] [PubMed] [Google Scholar]
  • 33. Pfeffer LM, Dinarello CA, Herberman RB, Williams BR, Borden EC, Bordens R, Walter MR, Nagabhushan TL, Trotta PP, Pestka S. Biological properties of recombinant alpha‐interferons: 40th anniversary of the discovery of interferons. Cancer Res 1998; 58: 2489–99. [PubMed] [Google Scholar]
  • 34. Gutterman JU. Cytokine therapeutics: lessons from interferon alpha. Proc Natl Acad Sci USA 1994; 91: 1198–205. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 35. Matsubara N, Fuchimoto S, Orita K. Antiproliferative effects of natural human tumor necrosis factor‐alpha, interferon‐alpha, and interferon‐gamma on human pancreatic carcinoma cell lines. Int J Pancreatol 1991; 8: 235–43. [DOI] [PubMed] [Google Scholar]
  • 36. Watanabe T, Fuchimoto S, Matsubara N, Iwagaki H, Orita K. Anti‐prolifera‐tive effect on human pancreatic cancer cells of natural human tumour necrosis factor‐beta combined with natural human interferon‐alpha or interferon‐gamma. J Int Med Res 1992; 20: 112–20. [DOI] [PubMed] [Google Scholar]
  • 37. Suzuki K, Aoki K, Ohnami S, Yoshida K, Kazui T, Kato N, Inoue K, Kohara M, Yoshida T. Adenovirus‐mediated gene transfer of interferon α improves dimethynitrosamine‐induced liver cirrhosis in rat model. Gene Ther 2003; 10: 765–73. [DOI] [PubMed] [Google Scholar]
  • 38. http://www.nih.gov/news/panelrep.html
  • 39. http://www.fda.gov/fdac/features/2000/500_gene.html
  • 40. Marshall E. Gene therapy, a suspect in leukemia‐like disease. Science 2002; 298: 34–5. [DOI] [PubMed] [Google Scholar]

Articles from Cancer Science are provided here courtesy of Wiley

RESOURCES